Evidence map›Paper›PMID 27558259›Full record

SynthesisBMC cancer2016

Systems-level effects of ectopic galectin-7 reconstitution in cervical cancer and its microenvironment.

Juan Carlos Higareda-Almaraz, Juan S Ruiz-Moreno, Jana Klimentova, Daniela Barbieri, Raquel Salvador-Gallego, Regina Ly, Ilse A Valtierra-Gutierrez, Christiane Dinsart, Gabriel A Rabinovich, Jiri Stulik and 2 more

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Galectin-7 in Epithelial Homeostasis and Carcinomas.International journal of molecular sciences · 2017
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 5 countries.

Juan Carlos Higareda-AlmarazDivision of Viral Transformation Mechanisms, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 242, 69120, Heidelberg, Germany.
Juan S Ruiz-MorenoDivision of Viral Transformation Mechanisms, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 242, 69120, Heidelberg, Germany.
Jana KlimentovaDepartment of Molecular Pathology and Biology, Faculty of Military Health Sciences, University of Defense, 500 01, Hradec Králové, Czech Republic.
Daniela BarbieriDivision of Viral Transformation Mechanisms, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 242, 69120, Heidelberg, Germany.
Raquel Salvador-GallegoDivision of Viral Transformation Mechanisms, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 242, 69120, Heidelberg, Germany.
Regina LyDivision of Viral Transformation Mechanisms, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 242, 69120, Heidelberg, Germany.
Ilse A Valtierra-GutierrezDepartment Biologie II, Ludwig-Maximilians-Universität München, Planegg-Martinsried, Germany.
Christiane DinsartDivision of Tumor Virology, German Cancer Research Center (DKFZ), 69,120, Heidelberg, Germany.
Gabriel A RabinovichLaboratorio de Inmunopatología, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas, C1428, Ciudad de Buenos Aires, Argentina.
Jiri StulikDepartment of Molecular Pathology and Biology, Faculty of Military Health Sciences, University of Defense, 500 01, Hradec Králové, Czech Republic.
Frank RöslDivision of Viral Transformation Mechanisms, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 242, 69120, Heidelberg, Germany. f.roesl@dkfz-heidelberg.de.
Bladimiro Rincon-OrozcoDivision of Viral Transformation Mechanisms, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 242, 69120, Heidelberg, Germany. blrincon@uis.edu.co.ORCID 0000-0001-5323-0422
German Cancer Research Center · DEUniversity of Defence · CZConsejo Nacional de Investigaciones Científicas y Técnicas · ARIndustrial University of Santander · COLudwig-Maximilians-Universität München · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGalectin-7 (Gal-7) is negatively regulated in cervical cancer, and appears to be a link between the apoptotic response triggered by cancer and the anti-tumoral activity of the immune system. Our understanding of how cervical cancer cells and their molecular networks adapt in response to the expression of Gal-7 remains limited.

methodsMeta-analysis of Gal-7 expression was conducted in three cervical cancer cohort studies and TCGA. In silico prediction and bisulfite sequencing were performed to inquire epigenetic alterations. To study the effect of Gal-7 on cervical cancer, we ectopically re-expressed it in the HeLa and SiHa cervical cancer cell lines, and analyzed their transcriptome and SILAC-based proteome. We also examined the tumor and microenvironment host cell transcriptomes after xenotransplantation into immunocompromised mice. Differences between samples were assessed with the Kruskall-Wallis, Dunn's Multiple Comparison and T tests. Kaplan-Meier and log-rank tests were used to determine overall survival.

resultsGal-7 was constantly downregulated in our meta-analysis (p < 0.0001). Tumors with combined high Gal-7 and low galectin-1 expression (p = 0.0001) presented significantly better prognoses (p = 0.005). In silico and bisulfite sequencing assays showed de novo methylation in the Gal-7 promoter and first intron. Cells re-expressing Gal-7 showed a high apoptosis ratio (p < 0.05) and their xenografts displayed strong growth retardation (p < 0.001). Multiple gene modules and transcriptional regulators were modulated in response to Gal-7 reconstitution, both in cervical cancer cells and their microenvironments (FDR < 0.05 %). Most of these genes and modules were associated with tissue morphogenesis, metabolism, transport, chemokine activity, and immune response. These functional modules could exert the same effects in vitro and in vivo, even despite different compositions between HeLa and SiHa samples.

conclusionsGal-7 re-expression affects the regulation of molecular networks in cervical cancer that are involved in diverse cancer hallmarks, such as metabolism, growth control, invasion and evasion of apoptosis. The effect of Gal-7 extends to the microenvironment, where networks involved in its configuration and in immune surveillance are particularly affected.

Indexed as

FemaleGalectinsHumansTumor MicroenvironmentUterine Cervical NeoplasmsGalectinsLGALS7 protein, humanCervical cancerDifferential network analysisGalectin-7Microenvironment crosstalk

Identifiers

PMID27558259
PMCPMC4997669
OpenAlexW2517865846

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.